l e t t e r S Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in AA are not defined limiting clinical development of rational targeted therapies 1 . Genome-wide association studies (GWAS) 2 implicated ligands for the NKG2D receptor (product of the KLRK1 gene) in disease pathogenesis. Here, we show that cytotoxic CD8 + NKG2D + T cells are both necessary and sufficient for the induction of AA in mouse models of disease. Global transcriptional profiling of mouse and human AA skin revealed gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-g (IFN-g) response and upregulation of several g-chain (g c ) cytokines known to promote the activation and survival of IFN-g-producing CD8 + NKG2D + effector T cells. Therapeutically, antibody-mediated blockade of IFN-g, interleukin-2 (IL-2) or interleukin-15 receptor b (IL-15Rb) prevented disease development, reducing the accumulation of CD8 + NKG2D + T cells in the skin and the dermal IFN response in a mouse model of AA. Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IFN-g and g c cytokine receptors, eliminated the IFN signature and prevented the development of AA, while topical administration promoted hair regrowth and reversed established disease. Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.
Alopecia areata is a T cell-mediated autoimmune disease characterized phenotypically by hair loss and, histologically, by infiltrating T cells surrounding the hair follicle bulb (reviewed in ref. 1) . Previous studies have shown that transfer of total T cells (but not B cells or sera) can cause the disease in human xenograft models 3 , as well as in C3H/HeJ mice 4 , a mouse strain that develops spontaneous AA with considerable similarity to human AA. Broad-acting intralesional steroids are the most commonly used therapy for AA, with varying success. Progress in developing effective, rationally targeted therapies has been limited by our lack of mechanistic understanding of the underlying key T cell inflammatory pathways in AA.
We 2 and others 5 have previously identified a cytotoxic subset of CD8 + NKG2D + T cells within the infiltrate surrounding human AA hair follicles, as well as concomitant upregulation in the follicle itself of the 'danger signals' ULBP3 (ref. 2) and MICA 5 , two NKG2D ligands (NKG2DLs) whose importance in disease pathogenesis has also been suggested by genome-wide association studies 2 .
To determine the contribution of CD8 + NKG2D + T cells to AA pathogenesis, we used the C3H/HeJ mouse model 6 , which spontaneously develops alopecia and recapitulates many pathologic features of human AA 7 . In lesional skin biopsies from alopecic mice, CD8 + NKG2D + T cells infiltrate the epithelial layers of the hair follicle, which overexpress the NKG2DLs, H60 and Rae-1, analogous to what has been observed in skin biopsies of human AA 2 (Fig. 1a,b and Supplementary Fig. 1a,b) . Flow cytometric analysis of the CD45 + leukocyte population in the skin revealed a marked increased number of CD8 + NKG2D + T cells in the skin of diseased C3H/HeJ mice, in conjunction with cutaneous lymphadenopathy and increased total cellularity, as compared with disease-free C3H/HeJ mice (Fig. 1c,d) . Other cell types, including CD4 + T cells 4 and mast cells 8 , were present in much smaller numbers ( Supplementary Fig. 1c and data not shown).
The immunophenotype of the skin-infiltrating CD8 + T cells in mice with AA was similar to that of the CD8 + NKG2D + population found in the cutaneous lymph nodes: CD8αβ + effector memory T cells (T EM , CD8 hi CD44 hi CD62L low CD103 + ) bearing several natural killer (NK) immunoreceptors, including CD49b and NKG2A, NKG2C and NKG2E ( Fig. 1e and Supplementary Fig. 1d ). These CD8 + T EM cells expressed high levels of IFN-γ and exhibited NKG2D-dependent cytotoxicity against ex vivo-expanded syngeneic dermal sheath target cells (Fig. 1f) . Gene expression analysis of the CD8 + NKG2D + T cells isolated from alopecic C3H/HeJ lymph node cells using l e t t e r S 1 0 4 4 VOLUME 20 | NUMBER 9 | SEPTEMBER 2014 nature medicine RNA-seq demonstrated a transcriptional profile characteristic of effector cytotoxic T lymphocytes (CTLs) 9, 10 and identified several additional NK-specific transcripts (Supplementary Table 1 and Supplementary Fig. 2 ). We next evaluated the requirement of these CD8 + T EM cells in disease pathogenesis. Transfer of cytotoxic CD8 + NKG2D + cells or total lymph node cells from diseased mice induced AA in all five healthy C3H/HeJ recipients by 14 weeks after transfer, whereas lymph node cell populations depleted of NKG2D + cells were unable to transfer disease (Fig. 1g) . Thus, CD8 + NKG2D + T cells are the dominant cell type in the dermal infiltrate and are necessary and sufficient for T cell-mediated transfer of AA.
To characterize the transcriptional profile of AA lesional skin from C3H/HeJ mice as well as human AA, we performed Affymetrix microarray analyses to identify differentially expressed genes in skin between individuals with AA and skin from control individuals without disease ( Supplementary Fig. 3 and Supplementary Tables 2 and 3) Three gene expression signatures were identified in lesional skin: IFN response genes, such as those encoding the IFN-inducible chemokines CXCL-9, CXCL-10 and CXCL-11 ( Supplementary  Figs. 3 and 4) , several key CTL-specific transcripts, such as those encoding CD8A and granzymes A and B, and γ c cytokines and their receptors, such as the transcripts for interleukin-2 (IL-2) and IL-15, in both human and mouse AA skin. As IL-2Rα was previously shown to be expressed on infiltrating lymphocytes surrounding human AA hair follicles 11 , we performed immunofluorescence analysis for both IL-15 and its chaperone receptor IL-15Rα to identify the source of IL-15 in the skin. We detected a marked upregulation of both components in AA hair follicles in both human and mouse AA and found IL-15Rβ expressed on infiltrating CD8 + T cells in humans CD8 + T cells [14] [15] [16] . To test the efficacy of IFN-γ-and γ c -targeted therapies in vivo, we used the well-established graft model of AA, in which skin grafts from mice with spontaneous AA are transferred onto the backs of unaffected 10-week-old recipient C3H/HeJ mice. In this model, AA develops reliably in 95-100% of grafted recipients within 6-10 weeks 7 , allowing us to test interventions aimed at either preventing or reversing disease. The role of IFN-γ in AA was previously investigated using both knockout studies and administration of IFN-γ, where IFN-γ-deficient mice were resistant and exogenous IFN-γ precipitated disease 17, 18 . Administration of neutralizing antibodies to IFN-γ at the time of grafting prevented AA development in grafted recipients and abrogated major histocompatibility complex (MHC) upregulation and CD8 + NKG2D + infiltration in the skin (Fig. 2a-c) . Likewise, a role for IL-2 in AA pathogenesis was previously established using genetic experiments in which IL-2 haploinsufficiency on the C3H/HeJ background conferred resistance to disease by about 50% using the graft model 19 , and this role is supported by our genome-wide association studies in humans 2 . Systemically administered blocking antibodies to either IL-2 ( Fig. 2d-f) or IL-15Rβ (Fig. 2g-i) prevented AA in grafted mice, blocked the accumulation of CD8 + NKG2D + T cells in the skin and abrogated MHC upregulation. However, IL-21 blockade failed to prevent the development of AA in grafted C3H/HeJ mice (Supplementary Fig. 7) . Notably, none of these blocking antibodies given alone was able to reverse established AA (data not shown).
We next asked whether we could recapitulate the effects of type I cytokine blockade by intervening downstream using small-molecule inhibitors of JAK kinases, which signal downstream of a wide range of cell surface receptors. In particular, IFN-γ receptors and γ c family receptors signal through JAK1/2 and JAK1/3, respectively 20 . JAK activation was shown by the presence of phosphorylated signal transducer and activator of transcription (STAT) proteins (pSTAT1, pSTAT3 and to a lesser extent pSTAT5) in human and mouse alopecic hair follicles, but not in normal hair follicles (Supplementary Fig. 8 ).
In in vitro-cultured dermal sheath cells from C3H/HeJ mice, exogenous IFN-γ increased STAT1 activation, whereas IFN-γ plus TNF-α increased surface IL-15 expression (Supplementary Fig. 9a,b) .
Ruxolitinib, a US Food and Drug Administration (FDA)-approved small-molecule inhibitor of the JAK1/2 kinases (JAK selectivity is JAK1 = JAK2>Tyk2>>>JAK3) 21 critical for IFN-γR signaling inhibited these responses (Supplementary Fig. 9a,b) . In cultured CTL effectors from C3H/HeJ mice, the FDA-approved small-molecule JAK3 inhibitor tofacitinib (JAK3>JAK1>>JAK2 selectivity) 22 blocked IL-15-triggered pSTAT5 activation (Supplementary Fig. 9c ). Tofacitinib also blocked killing of dermal sheath cells (Supplementary Fig. 9d ) and IL-15-induced upregulation of granzyme B and IFN-γ expression (Supplementary Fig. 9e ). To test whether inhibition of these signaling pathways would be therapeutically effective in vivo, we systemically administered ruxolitinib (Fig. 3a-c) and tofacitinib (Fig. 3f-h ) at the time of grafting and found that they prevented the development of AA and the expansion of CD8 + NKG2D + T cells in all grafted recipients. The skin of mice treated with either drug showed no histological signs of inflammation (Fig. 3d,i) . Global transcriptional analysis of whole-skin biopsies showed that both drugs also blocked the dermal inflammatory signature, as measured by Alopecia Areata Disease Activity Index (ALADIN, Fig. 3e,j) , and Gene Expression Dynamic Index (GEDI) analysis (Supplementary Fig. 10 ) 23 .
We next asked whether systemic tofacitinib treatment could reverse established disease by initiating therapy 7 weeks after grafting, a time point at which all mice had developed extensive AA. Systemic therapy resulted in substantial hair regrowth all over the body, reduced the frequency of CD8 + NKG2D + T cells and reversed histological markers of disease (Supplementary Fig. 11 ), all of which persisted 2-3 months after the cessation of treatment.
Next, to test a more clinically relevant route of delivery, we asked whether topical administration of protein tyrosine kinase inhibitors could reverse established AA in mice with kinetics similar to those of systemic delivery. In established disease, we found that topical ruxolitinib and topical tofacitinib were both highly effective in reversing disease in treated lesions (applied to back skin). A full coat of hair emerged in the ruxolitinib-or tofacitinib-treated mice by 7 weeks of treatment (data not shown), and we observed complete hair regrowth within 12 weeks following topical therapy (Fig. 4a,b) . Topical therapy was associated with a markedly reduced proportion of CD8 + NKG2D + T cells in the treated skin and lymph node (Fig. 4c) , normalization of the ALADIN transcriptional signature (Fig. 4d) , reversal of histological markers of disease (Fig. 4e) and correction of the GEDI in all treated mice (Supplementary Fig. 12) . Notably, untreated areas on the abdomen remained alopecic (Fig. 4a and Supplementary Fig. 13 ), demonstrating that topical therapy acted locally and that the observed therapeutic effects were not the result of systemic absorption. These effects were visible as early as 2-4 weeks after the onset of treatment (Supplementary Fig. 14) and persisted 2-3 months after the cessation of treatment (Fig. 4a) .
To test the efficacy of JAK inhibitors in human subjects with AA, we treated three patients with moderate to severe disease orally with ruxolitinib, 20 mg twice daily. Ruxolitinib is currently FDA-approved for the treatment of myelofibrosis 24, 25 , a disease driven by wild-type and mutant JAK2 signaling downstream of hematopoietic growth factor receptors. In addition, small clinical studies using topical ruxolitinib in psoriasis 26 have demonstrated anti-inflammatory activity that may be due to interruption of the IL-17 signaling axis. All three ruxolitinibtreated patients exhibited near-complete hair regrowth within 3 to 5 months of oral treatment (Fig. 4f and Supplementary Figs. 15 and  16) . Comparison of biopsies obtained at baseline and after 12 weeks of treatment demonstrated reduced perifollicular T cell infiltration, reduced follicular expression of human leukocyte antigen class I and class II expression (Fig. 4g) and normalization of the ALADIN inflammatory and hair keratin signatures following treatment (Fig. 4h,i) .
Taken together, our data suggest CD8 + NKG2D + T cells promote AA pathogenesis, acting as cytolytic effectors responsible for autoimmune attack of the hair follicle (Supplementary Fig. 17) . We postulate that IFN-γ produced by CD8 T cells leads to the collapse of immune privilege in the hair follicle 27 , inducing further production of IL-15 (ref. 28) (Supplementary Figs. 5 and 6 ) and a feed-forward loop that promotes type I cellular autoimmunity. The clinical response of a small number of patients with AA to treatment with the JAK1/2 inhibitor ruxolitinib suggests future clinical evaluation of this compound or other JAK protein tyrosine kinase inhibitors currently in clinical development is warranted in AA 29 .
MeTHoDS
Methods and any associated references are available in the online version of the paper.
Accession codes.
Microarray and RNA-seq data were deposited in Gene Expression Omnibus with accession numbers GSE45657, GSE45512, GSE45513, GSE45514, GSE45551 and GSE58573. 
oNLINe MeTHoDS
Mice. 7-to 10-week-old female C57BL/6 and C3H/HeJ mice (Jackson Laboratories, Bar Harbor, ME) were used and maintained under specific pathogen-free conditions. Experiments were performed in compliance with institutional guidelines as approved by the Institutional Animal Care and Use Committee of Columbia University Medical Center.
Transfer of alopecia areata using grafted C3H/HeJ skin. Normal-haired C3H/HeJ mice were grafted at 8 weeks of age (during the second telogen) with skin from a C3H/HeJ mouse that developed AA spontaneously, as described previously 7 . In brief, mice spontaneously affected with AA were euthanized, and full thickness skin grafts of approximately 2 cm in diameter were removed and grafted to normal-haired C3H/HeJ mice. All experiments included 10 grafted mice (5 treated and 5 untreated) and 3 sham grafted mice (mice grafted with autologous grafts). Hair loss typically began at around 4-6 weeks after grafting. No sham grafted mouse developed hair loss.
Flow cytometric analysis of skin and cutaneous lymph nodes. To make a single-cell suspension of mouse skin, fat was removed from the overlying skin in cold PBS and then incubated in collagenase type I (2 mg/ml in PBS) at 32 °C for 75 min. After digestion, the skin was minced in RPMI/10% FBS, filtered through a 70-µM cell strainer and centrifuged at 1100g for 5 min. The pellet was resuspended in RPMI/10% FBS, filtered through a 40-µM cell strainer and spun at 400g for 5 min. The pellet was resuspended in FACS buffer (PBS/5% BSA), DAPI to gate on live cells and staining antibodies (listed in Supplementary Methods). Cutaneous lymph nodes were pooled, minced in RPMI, filtered through a 40-µM cell strainer, centrifuged at 400g for 5 min, stained and analyzed on a BD LSR II flow cytometer.
Transfer of T cell populations into recipient C3H/HeJ mice. For positive selection of T cell populations, lymph node cells were obtained from 5 C3H/HeJ alopecic mice, stained with anti-CD4, anti-CD8 and anti-NKG2D antibodies) and then sorted (BD Influx) to obtain two fractions: CD8 + NKG2D + T cells and CD8 + NKG2D − T cells. Antibody dilutions are given in the Supplementary Methods. Three to five 7-week-old C3H/HeJ mice per group were injected subcutaneously with two million sorted cells of each population. For negatively selected populations, NKG2D + cells were depleted by incubating total lymph node cells from 3 alopecic C3H/HeJ mice with biotinylated anti-NKG2D (CX5) and then with streptavidin-conjugated beads (Miltenyi) before removal on a Miltenyi magnetic column. Five million cells (either CD8/NKG2D-depleted or total lymph node cells) were suspended in 100 ul PBS and transferred into each of 5 mice by subcutaneous injection.
